Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY OF THE SENATE

05 FEB 14 AM 10: 12 LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

Registrant name	,	
Organization Novo Nordisk Pharmaceuticals, Inc.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Address Check if different than previously reported		v.
Address1 2401 Pennsylvania Ave., NW, Ste.# 300		
City Washington State DC	Zip Code 20	OO37 Country l
Principal place of business (if different than line 2) City Princeton State NJ	Zip Code 08	8540 Country
City 1. The lease number	or Country c, E-mail	5. Senate ID#
a. Contact Ivanic Deafix Full Name	y@novonordisk.com	28479
Mr. Michael Mawby 222	V@HOVOHOTUISK:COIT	6. House ID#
Client Name Self		36903
YPE OF REPORT 8. Year 2004 Midyear (January O. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report Termination Date		R Year End (July 1-Decer
YPE OF REPORT 8. Year 2004 Midyear (January O. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report Termination Date INCOME OR EXPENSES - Complete Either Line 1		11. No Lobbying
	2 OR Line 13	11. No Lobbying 13. Organizations
YPE OF REPORT 8. Year 2004 Midyear (January 9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ☐ ⇒ Termination Date INCOME OR EXPENSES - Complete Either Line 1 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period	2 OR Line 13	11. No Lobbying
YPE OF REPORT 8. Year 2004 Midyear (January 9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report Termination Date INCOME OR EXPENSES - Complete Either Line 1 12. Lobbying Firms	2 OR Line 13 EXPENSES relating to	11. No Lobbying 13. Organizations
PYPE OF REPORT 8. Year 2004 Midyear (January 9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report Termination Date Termination Date Termination Date 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was:	2 OR Line 13 EXPENSES relating to were:	11. No Lobbying 13. Organizations o lobbying activities for this rep
YPE OF REPORT 8. Year 2004 Midyear (January 9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report	EXPENSES relating to were: Less than \$10,000 \$10,000 or more	11. No Lobbying 13. Organizations o lobbying activities for this rep
YPE OF REPORT 8. Year 2004 Midyear (January 9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report	EXPENSES relating to were: Less than \$10,000 \$10,000 or more 14. REPORTING Maccounting method. S Method A. R Method B. R	11. No Lobbying 13. Organizations o lobbying activities for this rep

_ _ _ - - - -

LD-2DS (Rev. 4/03)

Page

gistrant Name No	ovo Nordisk Pharmac	euticals, Inc.	Client Name Novo Nordisk Pharmaceuticals, Ir
OBBYING ACT	FIVITY. Select as r	many codes as ne ient during the re	cessary to reflect the general issue areas in which to porting period. Using a separate page for each called.
. General issue a	rea code	dget/Appropriation	(one per page)
. Specific lobbyi	ng issues		Add page to continue specific issues description for this issue
FY 2005 Appro Education Prog		betes related acti	vities including funding for National Diabetes
h./*			ed Check if None
Senate	ongress and Federal	agencies contacto	Check if None
Senate House HHS CDC, NIDDK	individual who acte		
Senate House HHS CDC, NIDDK Name of each	individual who acte	d as a lobbyist in	this issue area Add a page to continue additing tobbyist
Senate House HHS CDC, NIDDK Name of each First Name	individual who acte Name Last Name	d as a lobbyist in	this issue area Add a page to continue additing tobbyist Covered Official Position (if applicable)
Senate House HHS CDC, NIDDK 3. Name of each First Name Michael	individual who acte Name Last Name Mawby	d as a lobbyist in	this issue area Add a page to continue additing lebbyistic Covered Official Position (if applicable) Chif Government Affairs Officer
Senate House HHS CDC, NIDDK Name of each First Name lichael	individual who acte Name Last Name Mawby McGill	d as a lobbyist in	this issue area Add a page to continue additing tobbyist Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs
Senate House HHS CDC, NIDDK 3. Name of each First Name Michael	individual who acte Name Last Name Mawby McGill	d as a lobbyist in	this issue area Add a page to continue additing tobbyist Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs
Senate House HHS CDC, NIDDK	individual who acte Name Last Name Mawby McGill	d as a lobbyist in	this issue area Add a page to continue additing lobbyists Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs
Senate House HHS CDC, NIDDK 3. Name of each First Name Michael	individual who acte Name Last Name Mawby McGill	d as a lobbyist in	this issue area Add a page to continue additing lobbyists Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs

Printed Name and Title	Michael Mawby, Chief Government Affairs Officer	
------------------------	---	--

Page_

Registrant Name _	Novo Nordisk Pharmace	uticals, Inc.	Client NameNovo Nordisk Pharmaceuticals, Inc
engaged in lobby	CTIVITY. Select as m ring on behalf of the clie equested. Attach addition	ent during the re	cessary to reflect the general issue areas in which the porting period. Using a separate page for each conneeded.
15. General issue	e area code	/right/Patent/Tra	demark (one per page)
16. Specific lobb	oying issues		Add page to continue specific issues description for this issue
	ne United States Patent and intellectual property is		Fee Modernization Act of 2003; related patent,
17. House(s) of	Congress and Federal a	gencies contact	ed Check if None
į.		•	
Senate House Commerce PTO 18. Name of each	ch individual who acted	as a lobbyist ir	
House Commerce PTO 18. Name of each	ch individual who acted Name Last Name	as a lobbyist ir	this issue area Add a page to continue additing totalyists to Covered Official Position (if applicable)
House Commerce PTO	Name		
House Commerce PTO 18. Name of each	Name Last Name		Covered Official Position (if applicable)
House Commerce PTO 18. Name of each First Name Michael	Name Last Name Mawby		Covered Official Position (if applicable) Chif Government Affairs Officer
House Commerce PTO 18. Name of each First Name Michael Steve	Name Last Name Mawby McGill		Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs
House Commerce PTO 18. Name of each First Name Michael Steve	Name Last Name Mawby McGill		Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs
House Commerce PTO 18. Name of each First Name Michael Steve	Name Last Name Mawby McGill		Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs
House Commerce PTO 18. Name of each First Name Michael Steve	Name Last Name Mawby McGill		Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs
House Commerce PTO 18. Name of each First Name Michael Steve	Name Last Name Mawby McGill		Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs

Printed Name and Title	Michael Mawby, Chief Government Affairs Officer	
LD-2DS (REV. 4/03)		Page_

₹egistrant Name	ovo Nordisk Pharmaceut	ticals, Inc.	Client NameNovo Nordisk Pharmaceuticals, Inc.
LOBBYING AC	TIVITV Select as mai	ny codes as ne it during the re	ecessary to reflect the general issue areas in which the eporting period. Using a separate page for each codneeded.
15. General issue:	HCR - Health	n Issues	(one per page)
16. Specific lobby	ing issues		Add page to continue specific issues description for this issue
S.1666, Diabe	tes Prevention and Trea	tment Act of 2	003; all sections.
HR 1916, Diat	etes Prevention Access	and Care Act	; all sections.
HR 3194, Diak	petes Self-Management	Training Act o	f 2003; all sections.
17 House(s) of C	Congress and Federal ag	encies contac	ted Check if None
Senate		·	
House HHS, CMS, C	n individual who acted a Name Last Name	as a lobbyist i	Covered Official Position (if applicable)
House HHS, CMS, C	n individual who acted a		Covered Official Position (if applicable) Chif Government Affairs Officer
House HHS, CMS, C 18. Name of each	n individual who acted a Name Last Name		Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs
House HHS, CMS, C 18. Name of each First Name Michael	n individual who acted a Name Last Name Mawby		Covered Official Position (if applicable) Chif Government Affairs Officer
House HHS, CMS, C 18. Name of each First Name Michael Steve	n individual who acted a Name Last Name Mawby McGill		Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs
House HHS, CMS, C 18. Name of each First Name Michael Steve	n individual who acted a Name Last Name Mawby McGill		Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs
House HHS, CMS, C 18. Name of each First Name Michael Steve	n individual who acted a Name Last Name Mawby McGill		Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs
House HHS, CMS, C 18. Name of each First Name Michael Steve	n individual who acted a Name Last Name Mawby McGill		Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs
House HHS, CMS, C 18. Name of each First Name Michael Steve	n individual who acted a Name Last Name Mawby McGill		Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs

Printed Name and Title	Michael Mawby, Chief Governme	ent Affairs Officer
------------------------	-------------------------------	---------------------

Page

	Novo Nordisk Pharmace	uticals, Inc.	Client Name Novo Nordisk Pharmaceuticals, Inc
LOBBYINGAO	CTIVITY. Select as ma	any codes as necent	essary to reflect the general issue areas in which thorting period. Using a separate page for each conteded.
15. General issue	e area code	licare/Medicaid	(one per page)
16. Specific lobb	ying issues		Add page to continue specific issues description for this issue
and Modornia	zation Act of 2003 with a nsulin delivery devices a	special emphasis	es provisions of the Medicare Prescription Drug s on ensuring that the regulations pertaining to the reflect the sense of Congress as embodied in the
17. House(s) of	Congress and Federal a	gencies contacted	1 Check if None
HHS, CMS, C			
First Name	ch individual who acted Name Last Name	as a lobbyist in t	Covered Official Position (if applicable)
First Name Michael	Name Last Name Mawby	1	Covered Official Position (if applicable) Chif Government Affairs Officer
First Name	Name Last Name Mawby McGill	1	Covered Official Position (if applicable) Chif Government Affairs Officer Associate Director, Government Affairs
First Name Michael Steve Peter	Name Last Name Mawby McGill Norman	Suffix	Covered Official Position (if applicable) Chif Government Affairs Officer

Printed Name and Title	Michael Mawby, Chief Government Affairs Officer
LD-2DS (REV. 4/03)	

Page .

Latanat Nama	Novo Nordisk Pharmac	euticals, Inc.	Client Name Novo Nordisk Pharmaceuticals, Inc.
)BBYINGA	CTIVITY. Select as the ying on behalf of the clequested. Attach additional additional control of the clequested.	many codes as nec ient during the rep tional page(s) as n	
. General issu	tAX - Tax e area code	kation/Internal Rev	enue Code (one per page)
. Specific lob	bying issues		Add page to continue specific issues description for this issue
strengthen s	support for passage of t	he R&D tax credit,	
	f Congress and Federal	l agencies contacto	ed Check if None
First Name	ach individual who act Name Last Name	ted as a lobbyist in	Covered Official Position (if applicable)
House 8. Name of e First Name Michael	Name Last Name Mawby		
House 8. Name of e First Name	Name Last Name		Covered Official Position (if applicable) Chif Government Affairs Officer

Page

Registrant Name Novo N	lordisk Pharm	aceuticals, Inc.	Client N	lame Novo Nordis	sk Pharmaceuticals,	Inc.
Information Upda	ate Page - (Complete ONI	LY where regi	stration inform	ation has changed	<u>1</u>
20. Client new address						
Address		*.			_	
City			State	Zip Code	Countr	y
21. Client new principa	il place of busin	ness (if different th	nan line 20)			
City			State	Zip Code	Countr	у
22. New general descri						
					<u></u>	
LOBBYIST UPDA 23. Name of each pre	TE viously repor	ted individual w	ho is no longer	expected to act as	a lobbyist for the cl	ient sı
1	•		[3]			
2	\$		3.7 × 4 \$4.5			
ISSUE UPDATE				ind the code to se	elect helow.	
24. General lobbying	issues that n o	longer pertain	· !	The the code to st	Signe Bollow.	
- · · · · · · · · · · · · · · · · · · ·						
AFFILIATED OR 25. Add the following						
Name		, , ,	Address		Principal place of l (city and state or	
,		Address	,		City	
		C/S/Z			State Cou	untry
		Address C/S/Z			City State	
26. Name of each pr	oviovely repo	rted organization	that is no long	er affiliated with t	he registrant or clier	nt
26. Name of each pr	eviously repor	2		3		
FOREIGN ENTI' 27. Add the followin		ties	·			
Name	Street Addres	Address s	(city ar	al place of business ad state or country)	Amount of contribution for lobbying activities	O pe ci
	City	State/Province			.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
		. *	City			
		•	State	Country		
28. Name of each pre	viously reporte	d foreign entity th	at no longer own	s, <u>or</u> controls, <u>or</u> is	affiliated with the reg	istran
affiliated organizat	11011	3	, ÷	5		
면 면		4		<u></u>		
[2]		بتا		<u> </u>		

Page _